Lv71
3670 积分 2024-04-09 加入
Dravet syndrome therapeutics: where are we, what works, and what’s next?
2天前
已完结
State‐of‐the‐art management of Dravet syndrome
2天前
已完结
Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease
28天前
已完结
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets
29天前
已完结
CLN2 Disease: Current Understandings, Challenges, and Future Directions
29天前
已完结
An ADAR2-mimic base editor for efficient C-to-U RNA editing in vivo
1个月前
已完结
RNA Editing-Mediated Correction of TP53 Nonsense Mutations via Lipid Nanoparticle-Delivered Circular ADAR-Recruiting RNAs
1个月前
已完结
RNA Editing-Mediated Correction of TP53 Nonsense Mutations via Lipid Nanoparticle-Delivered Circular ADAR-Recruiting RNAs
1个月前
已完结
Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer
1个月前
已完结
Programmable RNA base editing via targeted modifications
2个月前
已完结
皖公网安备34019202002308
